News

Novo Nordisk’s Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?

Novo Nordisk’s Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?

Novo Nordisk's GLP-1 pill is performing incredibly well, which is a good sign if you are considering buying the stock.

The Motley Fool